Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder

Journal of Child and Adolescent Psychopharmacology
Natchaya VanwongChonlaphat Sukasem

Abstract

The purpose of this study was to investigate the influence of CYP2D6 gene polymorphisms on plasma concentrations of risperidone and its metabolite in Thai children and adolescents with autism spectrum disorder (ASD). All 97 autism spectrum disorder patients included in this study had been receiving risperidone at least for 1 month. The CYP2D6 genotypes were determined by real-time polymerase chain reaction (PCR)-based allelic discrimination for CYP2D6*4, *10, and *41 alleles. Plasma concentrations of risperidone and 9-hydroxyrisperidone were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Among the 97 patients, the most important nonfunctional alleles (CYP2D6*4 and *5) were detected, whereas the most common allele was CYP2D6*10 (55.9%). CYP2D6 genotyping revealed 90 (92.78%) patients to be extensive metabolizers (EM) and 7 (7.22%) to be intermediate metabolizers (IM). Plasma levels of risperidone were significantly higher in individuals with CYP2D6*5/*10 (p = 0.02), CYP2D6*10/*10 (p = 0.04), and CYP2D6*10/*41 (p = 0.04). Additionally, the plasma concentration of risperidone/9-OH risperidone ratio in patients with a CYP2D6 activity score of 0.5 were significantly higher than those with a CYP2D6 activity...Continue Reading

References

Aug 23, 2002·Journal of Pharmaceutical and Biomedical Analysis·S H GanZ Wan
Nov 18, 2003·Naunyn-Schmiedeberg's Archives of Pharmacology·Ulrich M ZangerMichel Eichelbaum
Nov 27, 2004·European Archives of Psychiatry and Clinical Neuroscience·Michael RiedelH J Möller
Jan 27, 2005·The Journal of Clinical Psychiatry·Jose de LeonPeter J Wedlund
Aug 11, 2007·Journal of Child and Adolescent Psychiatric Nursing : Official Publication of the Association of Child and Adolescent Psychiatric Nurses, Inc·Lawrence ScahillMaryellen Pachler
Nov 1, 2007·Clinical Pharmacology and Therapeutics·A GaedigkJ S Leeder
Nov 6, 2007·Journal of Child and Adolescent Psychopharmacology·Wolfgang AichhornGeorg Kemmler
Aug 19, 2008·Therapeutic Drug Monitoring·Arzu GunesMaria Gabriella Scordo
Feb 17, 2009·Pediatric Research·Eric Fombonne
Oct 13, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Nov 12, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
May 25, 2010·Biochemical and Biophysical Research Communications·Magnus Ingelman-Sundberg, Sarah C Sim
Jun 22, 2010·European Journal of Clinical Pharmacology·Nikolina JovanovićAlma Mihaljević Peleš
Jul 6, 2010·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Igor LocatelliIztok Grabnar
Nov 3, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Roberto Canitano, Valeria Scandurra
Mar 18, 2011·Clinical Pharmacology and Therapeutics·J J SwenH-J Guchelaar
May 1, 2012·Brain & Development·Arianna BenvenutoPaolo Curatolo
May 23, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Sergi MasAmalia Lafuente
Jun 30, 2012·Human Psychopharmacology·Yutaro SuzukiToshiyuki Someya
Mar 7, 2013·The Annals of Pharmacotherapy·Andrea L CartwrightMary H H Ensom
Mar 15, 2013·Clinical Pharmacology and Therapeutics·J K HicksUNKNOWN Clinical Pharmacogenetics Implementation Consortium
Oct 25, 2013·International Review of Psychiatry·Andrea Gaedigk
Mar 20, 2014·European Journal of Clinical Pharmacology·Buster MannheimerErik Eliasson
May 16, 2014·Developmental Medicine and Child Neurology·Ilan YoungsterMatitiahu Berkovitch
Oct 16, 2014·Expert Opinion on Drug Metabolism & Toxicology·Adrián LLerenaEduardo Tarazona-Santos

❮ Previous
Next ❯

Citations

Nov 4, 2017·Journal of Personalized Medicine·Ida AkaSara L Van Driest
Jan 26, 2018·Basic & Clinical Pharmacology & Toxicology·Chonlaphat SukasemPenkhae Limsila
Jan 22, 2020·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Daria PiacentinoAndreas Conca
Jan 21, 2019·Pediatric Research·Kazeem A OshikoyaSara L Van Driest
Jan 7, 2020·Mass Spectrometry Reviews·Jia-Jia CuiJi-Ye Yin
Jul 10, 2020·British Journal of Clinical Pharmacology·Sanne Maartje KloosterboerBirgit C P Koch
Mar 1, 2017·Pharmacogenomics·Jacob T BrownJeffrey R Bishop
Oct 20, 2020·Journal of Child and Adolescent Psychopharmacology·Abdullah Al MarufChad Bousman
Nov 24, 2020·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Kazunari YoshidaDaniel J Müller
Jun 8, 2021·Drug Metabolism and Pharmacokinetics·Chonlaphat SukasemNapatrupron Koomdee

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
PCR

Software Mentioned

SPSS
Analyst

Related Concepts

Related Feeds

Autism: Treatment Targets

The absence of effective treatments for autism are due to the high clinical and genetic heterogeneity between affected individuals, restricted knowledge of the underlying pathophysiological mechanisms, and the lack of reliable diagnostic biomarkers. Identification of more homogenous biological subgroups is therefore essential for the development of novel treatments based on the molecular mechanisms underpinning autism and autism spectrum disorders. Find the latest research on autism treatment targets here.

Autism

Autism spectrum disorder is associated with challenges with social skills, repetitive behaviors, and often accompanied by sensory sensitivities and medical issues. Here is the latest research on autism.